

Pharmacotherapy Frontiers 2009



Saturday, April 25, 2009

7:30 am – 12:25 pm

Masur Auditorium
Clinical Center (Building 10)
National Institutes of Health
Bethesda, Maryland

7:30 – 8:15

Registration

8:15 – 8:25

Welcome

Robert DeChristoforo, MS, FASHP
Chief, Pharmacy Department, Clinical Center, NIH

8:25 – 8:30

Session 1 Introduction

James Schlick, RPh, MBA
*Inpatient Section Chief
Pharmacy Department, Clinical Center, NIH*

8:30 – 9:20

FDA's Initiatives on Drug Safety and Risk Communication

Steven F. Osborne, MD
*Executive Director, Drug Safety Oversight Board
FDA Center for Drug Evaluation and Research*

9:20 – 10:10

FDA Recall Program

Michael J. Verdi
*Senior Recall Coordinator
FDA Office of Enforcement*

10:10 – 10:40

Break

10:40 – 10:45

Session 2 Introduction

Sakar Wahby, Pharm.D
Oncology Pharmacist, Clinical Center, NIH

10:45 – 11:35

Prostate Cancer Update

Barry Goldspiel, Pharm.D, BCOP
*Deputy Chief
Pharmacy Department, Clinical Center, NIH*

11:35 – 12:25

New Anti-rheumatic Drugs

Frank Pucino, Pharm.D
*Clinical Researcher, National Institute of Arthritis and Musculoskeletal
and Skin Diseases
Pharmacy Department, Clinical Center, NIH*

The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. These presentations meet the ACPE criteria for one contact hour (0.1 CEUs) each of continuing education credit. Statements of credit will be mailed to participants within 60 days to those who successfully complete one or more presentations in the program. Successful completion of a presentation requires attendance at the entire presentation and completion of the presentation's post-test and program evaluation form. The post-test and evaluation form must be **submitted online within 10 days** of the conclusion of the program. This program is fully supported by the National Institutes of Health and has no other sponsor.

ACPE Universal Program numbers: (Pharmacists):

025-999-09-101-L03-P FDA's Initiatives on Drug Safety and Risk Communication

025-999-09-103-L03-P FDA Recall Program

025-999-09-100-L01-P Prostate Cancer Update

025-999-09-102-L01-P Emerging Drug Therapies for Rheumatoid Arthritis

